Compare LDI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LDI | PRTA |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 542.4M | 449.7M |
| IPO Year | 2021 | 2013 |
| Metric | LDI | PRTA |
|---|---|---|
| Price | $0.87 | $9.03 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $3.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 2.8M | 471.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | N/A | ★ $814,000.00 |
| Revenue This Year | $17.58 | $1,111.38 |
| Revenue Next Year | $13.99 | N/A |
| P/E Ratio | ★ N/A | $35.73 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.83 | $7.73 |
| 52 Week High | $5.05 | $11.80 |
| Indicator | LDI | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 37.79 | 51.70 |
| Support Level | $0.83 | $8.91 |
| Resistance Level | $1.22 | $9.36 |
| Average True Range (ATR) | 0.08 | 0.41 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 12.37 | 70.19 |
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.